Centrophenoxine

Throughout the ages and across many cultures, humans have been obsessed with life extension and immortality. Legends revolving around magical substances like the Elixir of Life are found in cultures as diverse as Ancient Mesopotamia and Japan. Although we can reasonably deduce that no such substance exists, there are certainly compounds that help slow certain aspects of aging. In the world of nootropics, one supplement stands out, centrophenoxine.

As one of the earliest nootropics to be synthesized, centrophenoxine has a wealth of research to support its role in enhancing cognition and increasing brain health to a remarkable extent.

This tried-and-true nootropic (also known as meclofenoxate) is an ester that combines two compounds, DMAE and pCPA. DMAE is a natural compound found in several foods commonly considered “brain foods.” The primary reason DMAE is good for the brain is that it is a source of choline. Choline allows the optimization and production of acetylcholine, a significant neurotransmitter involved in memory and learning. (Malanga, 2012)

A problem arises with DMAE alone; it has difficulty crossing the blood-brain barrier. This problem is remedied by the combination in centrophenoxine of pCPA in an esterified form, which seamlessly penetrates the blood-brain barrier. (Zs-Nagy, 1994)

However, centrophenoxine does not appear to simply mimic what is expected from DMAE alone. When considering how universally effective this nootropic is, we should consider that studies have shown both positive benefits for those with cognitive degeneration and in the healthy.

A study of patients with dementia discovered nearly twice the number of people in the centrophenoxine-treated group experienced cognitive improvements compared to the placebo group. (Pék, 1998) When administering centrophenoxine to healthy patients, researchers discovered an increase in long-term memory capacity, and an increase in mental alertness. (Marcer, 1977)

When considering nootropics, we should consider which features truly define a particular supplement. There are many nootropics with admirable qualities that overlap but some have special features that we can not expect in every noot. In surveying the research on centrophenoxine, the prominent effect is clearly its anti-aging effects on the brain, and there is even strong indication that it may increase lifespan.

Quantitative biochemical studies on human glial cells treated with centrophenoxine discovered a number of phenomenal effects. The amount of accumulated lipofuscin, lipid-containing deposits that accumulate in the brain as we age, are reduced by this nootropic. In addition to this, the glial cells showed enhanced metabolic functioning and delayed cellular aging. (Ludwig-Festl, 1983)

Whether if delaying or reversal of the aging-process in the brain translates to a longer lifespan can not be known definitively at this point. However, an astonishing discovery was made in a study on mice. The survival time of the mice treated with centrophenoxine was increased by 29.5 to 39.7 percent respectively. (Hochschild, 1973)

The power of rejuvenation found in this long-lived nootropic makes it a modern Elixir of Life. It will not make you immortal, as any sane person will realize but, what it does offer is a realistic but remarkable boon to our brains and our lives.

Double Wood supplements provides potent and effective Centrophenoxine capsules:

Double Wood Centrophenoxine

 

References and Works Cited

Malanga G, Aguiar MB, Martinez HD, Puntarulo S. New insights on dimethylaminoethanol (DMAE) features as a free radical scavenger. Drug Metab Lett. 2012 Mar;6(1):54-9. doi: 10.2174/187231212800229282. PMID: 22300295.

Zs-Nagy I. A survey of the available data on a new nootropic drug, BCE-001. Ann N Y Acad Sci. 1994 Jun 30;717:102-14. doi: 10.1111/j.1749-6632.1994.tb12077.x. PMID: 8030826.

Pék G, Fülöp T, Zs-Nagy I. Gerontopsychological studies using NAI (‘Nürnberger Alters-Inventar’) on patients with organic psychosyndrome (DSM III, Category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial. Arch Gerontol Geriatr. 1989 Jul;9(1):17-30. doi: 10.1016/0167-4943(89)90021-6. PMID: 2506844.

Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. Age Ageing. 1977 May;6(2):123-31. doi: 10.1093/ageing/6.2.123. PMID: 329662.

Ludwig-Festl M, Gräter B, Bayreuther K. Erhöhung von Zellstoffwechselleistungen in normalen, diploiden, menschlichen Glia-Zellen in stationären Zellkulturen induziert durch Meclofenoxat [Increase in cell metabolism in normal, diploid human glial cells in stationary cell cultures induced by meclofenoxate]. Arzneimittelforschung. 1983;33(4):495-501. German. PMID: 6191765.

Hochschild R. Effect of dimethylaminoethyl p-chlorophenoxyacetate on the life span of male Swiss Webster Albino mice. Exp Gerontol. 1973 Aug;8(4):177-83. doi: 10.1016/0531-5565(73)90024-7. PMID: 4147092.

By |2021-03-15T20:29:44+00:00March 15th, 2021|

About the Author:

A long-time nootropics enthusiast who is fascinated with the prospect of cognitive enhancement, John Ryan is an independent writer who received his University education at Northern Michigan University, as a history major, where he was inducted into the Phi Beta Kappa Society for academic excellence. While in Michigan, he also trained as an athlete at the United States Olympic Education Center, where he achieved the status of a multiple-time University All-American in Greco-Roman wrestling. He has authored several plays and a collection of poetry.